Investor Relations

Investor Relations

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator.

Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.


Copyright Nasdaq. Minimum 15 minutes delayed.


Jeanie D. Herbert
Sr. Director, Investor Relations

Burns McClellan
Ami Bavishi

Revance Therapeutics, Inc.
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400
Fax: (510) 742-3401

Transfer Agent
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)

Shareholder Correspondence should
be mailed to:
P.O. Box 505000
Louisville, KY  40233
Shareholder Overnight
correspondence should be sent to:
462 South 4th Street, Suite 1600
Louisville, KY 40202


Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools